Vest Financial 13F: Cuts WST Stake by $13M

Vest Financial reduced its holdings in West Pharmaceutical Services, Inc. WST by 18.6% during the quarter, according to a Form 13F filing with the SEC on October 21, 2026. The institutional investor sold 34,044 shares during the period to bring its total ownership down.

WST West Pharmaceutical Services, Inc.

$394.03 ▲ +42.89% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Vest Financial's West Pharmaceutical Services Position

Vest Financial cut its stake by 34,044 shares, leaving it with 148,537 shares of West Pharmaceutical Services. The remaining holdings carried an estimated value of $55,071,578 at the time of the filing. Prior to this reduction, the firm held 182,581 shares.

Other Institutional Activity in West Pharmaceutical Services

Other large funds also trimmed their holdings in the medical products maker during the period. Artisan Partners Limited Partnership cut its stake by 9.3%, ending with 2,411,792 shares valued at $950,318,398 after selling 246,123 shares. Bank Of New York Mellon Corporation reduced its position by 17.1% to hold 2,043,823 shares worth $805,327,574 following a sale of 422,180 shares. Generation Investment Management LLP lowered its holdings by 9.6%, selling 215,645 shares to finish with 2,028,322 shares valued at $799,219,715.

West Pharmaceutical Services, Inc. Stock Up 0.1%

West Pharmaceutical Services closed at $393.48 on October 21, 2026, and recently traded around $394.03 as of October 23, 2026. The share price sits just below its 52-week high of $397.16 and well above its 52-week low of $223.83. The stock trades above both its 50-day moving average of $361.15 and its 200-day moving average of $309.53.

Recent Earnings

West Pharmaceutical Services generated $3.33 billion in trailing twelve-month revenue alongside an earnings per share of $7.82. The company is scheduled to report its next financial results on October 29, 2026.

Dividend

West Pharmaceutical Services pays an annual dividend rate of $0.88 per share, yielding 0.26% with a payout ratio of 11.1%.

Insider Buying and Selling at West Pharmaceutical Services, Inc.

Company insiders executed several sales across the year. Chad Winters sold 896 shares on April 27, 2026, for $269,399. Annette F. Favorite sold multiple blocks, including 2,817 shares on April 27, 2026, for $859,753, 8,135 shares on September 8, 2026, for $2,772,489, and a final reported block later in the month.

Analysts Set New Price Targets

Wall Street firms covering the stock adjusted their views through recent months. Citigroup maintained a buy rating on August 3, 2026, lifting its target to $412.00, while UBS kept a buy rating and raised its target to $415.00 on September 9, 2026. Morgan Stanley upgraded the stock to overweight on September 22, 2026, with a $400.00 target. Barclays maintained an overweight rating on October 7, 2026, with a $440.00 target, and TD Cowen maintained a buy rating on October 13, 2026, with a $420.00 target. The consensus recommendation stands at a strong buy.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc., headquartered in Exton, Pennsylvania, designs and manufactures containment and delivery systems for injectable drugs and healthcare products worldwide. The firm operates through Proprietary Products and Contract-Manufactured Products segments, serving major pharmaceutical and biotech clients globally.

Bottom Line

Investors will watch closely for upcoming earnings results on October 29, 2026, to gauge whether the company can maintain its growth momentum. Institutional filings offer a backward-looking view of portfolio adjustments, which helps contextualize broader market sentiment alongside current valuations.